Browsing Tag
Latuda Tablets
2 posts
Lupin launches Lurasidone Hydrochloride in US, targeting $4.2bn bipolar depression market
Lupin launches Lurasidone Hydrochloride Tablets in the US, entering a $4.2B bipolar depression market with a full range of strengths.
February 22, 2023
Can Alembic Pharmaceuticals challenge Latuda with its FDA-approved Lurasidone Hydrochloride Tablets?
Find out how Alembic Pharmaceuticals’ FDA approval for Lurasidone Hydrochloride Tablets positions the drugmaker in the $3.7B bipolar depression market.
May 14, 2021